NeuroBo Pharmaceuticals to initiate Phase 1 Clinical Trial of DA-1726 for obesity
The FDA has cleared NeuroBo Pharmaceuticals’ Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM)...
top of page
Browse by category
Search
Browse by tag
bottom of page